Evaluation of Immunogenicity of Hepatitis B Vaccine in Hemodialysis Patients at Mazandaran Heart Center, Iran
Amir Shamshirian1, Shayan Alikhani2, Reza Alipoor3, Hamed Jafarpour4, Fatemeh Espahbodi5 and Soheil Azizi61Department of Laboratory Sciences, Faculty of Paramedicine, Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
2Hematology, Department of Hematology, Tarbiat Modares University, Tehran, Iran.
3Research Committee, Fasa University of Medical Sciences, Fasa, Iran.
4Faculty of Medicine, Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
5Endocrine research center, Imam Khomeini hospital, Mazandaran University of Medical Sciences, Sari, Iran.
6Department of Laboratory Sciences, Faculty of Paramedicine, Mazandaran University of Medical Sciences, Sari, Iran.
Corresponding Author E-mail: soheil_azizi@yahoo.com
Abstract: Hepatitis B Virus (HBV) infection is one of the most common issue worldwide. It is more common in hemodialysis (HD) patients which is sensitive to blood borne viral agents such as HBV more than other people and in terms of vaccine protection, immunogenicity of HBV vaccine in HD patients is still open for discussion. Therefore, aim of this study is to evaluating the immunogenicity of HBV vaccine in HD patients who admitted to the Mazandaran Heart Center hemodialysis unit in 2015. This cross-sectional study performed by using available data and Census method on all chronic HD patients in Mazandaran Heart Center in 2015. Patient’s information was extracted from their records with ethical points including age, gender, HBS Ab level and the number of dialysis per week. Data was analyzed using chi-square test and SPSS 16 software. Of all patients with a mean age of 54.7 ± 13.76 years, Positive anti-HCV was observed in 7(7%) of them. For immune response to HBV vaccine, 35% with no response, 32% with poor response and 33% with complete response were obtained. Also did not observed significant relationship between sex, age and the number of dialysis per week with immunization of HBV vaccine. In conclusion based on the observed information, the immunogenicity of hepatitis B vaccine in hemodialysis patients of Mazandaran Heart Center was moderate to low that the rate of response to vaccine were reasonable according to the previous studies.
Keywords: Hemodialysis patients; Hepatitis B virus; immune response Back to TOC